Cognitive topography imbalance in alcoholism and psychiatric comorbidity

peer reviewe

Compulsive Personality as Predictor of Response to Serotoninergic Antidepressants

Peer reviewe

Controlled Comparison of Milnacipran and Fluoxetine in Major Depression

The efficacy and the tolerance of milnacipran (100 mg/day), a second generation antidepressant which equipotently inhibits both noradrenaline and serotonin reuptake, was compared to fluoxetine (20 mg/day), a selective serotonin reuptake inhibitor, in two parallel groups of, respectively, 97 and 93 major depressive outpatients. The duration of the study was 6 weeks, with assessments every 2 weeks by means of the Montgomery and Asberg depression scale (MADRS), the Hamilton depression scale, the clinical global impressions (CGI), and a checklist of symptoms and side-effects. Results showed significant superiority of fluoxetine over milnacipran on most rating instruments: MADRS (P = 0.01) including five individual items, Hamilton depression scale (P = 0.002) including ten individual items, CGI of severity (P = 0.01) and therapeutical index (P = 0.002). On visual analogue scales assessing the clinical profile of the compounds, fluoxetine was rated as exhibiting more psychostimulating activity than milnacipran (P = 0.0008). The tolerance of the two antidepressants was very similar, with the exception of symptoms of dizziness which were more frequently reported with milnacipran (P = 0.01). These differences in efficacy favoring fluoxetine could result from the selection of a dose of milnacipran below the optimal therapeutic dose for this type of psychiatric patients or to the administration of the compounds in single daily intakes, whereas milnacipran possesses a plasma elimination half-life of only 7 h.Peer reviewe

Troubles psychiatriques et dangerosité

peer reviewe

Dépression: Intérêt de la variation contingente négative

peer reviewe

Milnacipran in obsessive-compulsive disorder: Study in one case

Obsessive-compulsive disorder is a severe pathology which is difficult to treat. Several recent studies have shown the efficacy of some antidepressants, particularly of the serotonergic type. Other findings, however, suggest a role for the noradrenergic neurotransmission. We present a trial using a new antidepressant, milnacipran, with both noradrenergic and serotonergic activity, in a patient presenting treatment-resistant obessive compulsive disorders. The role of the drug in the marked improvement of the patient's symptomatology is discussed

Milnacipran et trouble obsessionnel-compulsif: étude d'un cas

Le trouble obsessionnel-compulsif est une affection grave et difficile à traiter. Plusieurs études récentes ont montré une efficacité de certains antidépresseurs, particulièrement sérotoninergiques. Cependant, certains travaux plaident également pour un rôle des voies noradrénergiques. Nous discutons ici l'essai d'un nouvel antidépresseur, le milnacipran, à action noradrénergique et sérotoninergique, chez une patiente atteinte d'un trouble obsessionnel-compulsif rebelle. Le rôle possible de la médication dans la très nette amélioration de la symptomatologie obsessionnelle et dépressive est discuté

Contingent negative variation (CNV) in mood disorders

[No abstract available

Contingent Negative Variation and response to antidepressants

[No abstract available